

132nd MAINE LEGISLATURE

FIRST REGULAR SESSION-2025

Legislative Document

No. 538

H.P. 357

House of Representatives, February 11, 2025

An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives

Reference to the Committee on Health Coverage, Insurance and Financial Services suggested and ordered printed.

R(+ B. Hunt

ROBERT B. HUNT Clerk

Presented by Representative CLUCHEY of Bowdoinham. Cosponsored by Senator CARNEY of Cumberland and Representatives: Speaker FECTEAU of Biddeford, GRAMLICH of Old Orchard Beach, JULIA of Waterville, KUHN of Falmouth, MATHIESON of Kittery, MOONEN of Portland, WARREN of Scarborough, Senator: BAILEY of York.

1	Be it enacted by the People of the State of Maine as follows:
2	Sec. 1. 32 MRSA §13794, as amended by PL 2019, c. 34, §5, is further amended
3	by enacting at the end a new paragraph to read:
4	At the request of the practitioner prescribing the drug, the label for mifepristone,
5	misoprostol and their generic alternatives may include the name of the health care facility
6	that the practitioner is associated with instead of the name of the practitioner.
7	SUMMARY
8	This bill provides that, at the request of the practitioner prescribing the drug, the
9	prescription drug label for mifepristone, misoprostol and their generic alternatives may
10	include the name of the health care facility that the practitioner is associated with instead
11	of the name of the practitioner.